Clostridium difficile is a gram-positive, anaerobic, spore-forming bacterium that is the leading cause of nosocomial infections in hospitals in the United States. Critically ill patients are at high risk for C. difficile infection (CDI) and face potentially detrimental effects, including prolonged hospitalization, risk of recurrent disease, complicated surgery, and death. CDI requires a multidisciplinary approach to decrease hospital transmission and improve treatment outcomes. This article briefly reviews the current literature and guideline recommendations for treatment and prevention of CDI, with a focus on antibiotic treatment considerations including dosing, routes of administration, efficacy data, adverse effects, and monitoring parameters.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CNQ.0000000000000232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of order set implementation on appropriate treatment of community-acquired pneumonia (CAP).
Antimicrob Steward Healthc Epidemiol
January 2025
Ascension Borgess Hospital, Kalamazoo, MI, USA.
Objective: This study aimed to evaluate appropriate antimicrobial prescribing after implementing a pneumonia order set within a community teaching hospital.
Design: Retrospective chart review study.
Setting: 450-bed community teaching hospital.
TRPV4 modulates inflammatory responses and apoptosis in enteric glial cells triggered by Clostridioides difficile toxins A and B.
J Inflamm (Lond)
January 2025
Department of Morphology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.
Clostridioides difficile, a spore-forming anaerobic bacterium, is the primary cause of hospital antibiotic-associated diarrhea. Key virulence factors, toxins A (TcdA) and B (TcdB), significantly contribute to C. difficile infection (CDI).
View Article and Find Full Text PDFOral vancomycin induced flushing syndrome in a multiple myeloma patient: A case report and review of the literature.
Medicine (Baltimore)
November 2024
Department of Clinical Pharmacy, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: Patients with hematological malignancies are at high-risk of Clostridium difficile infection (CDI). Oral vancomycin is a first-line treatment for CDI. Vancomycin has been widely reported to induce flushing syndrome (also known as Red man syndrome), a well-known hypersensitivity reaction mostly occurs after intravenous administration.
View Article and Find Full Text PDFClinical impacts of utilizing ceftriaxone and metronidazole versus piperacillin/tazobactam in patients diagnosed with complicated diverticulitis.
Am J Surg
January 2025
Department of Pharmacy, Mayo Clinic Health System, Eau Claire, WI, USA.
Background: The optimal antibiotic regimen to empirically treat complicated diverticulitis has not been well established in guidelines.
Methods: A 5-year retrospective cohort study was conducted with 322 patients admitted to Mayo Clinic hospitals for complicated diverticulitis. Outcomes for 89 patients treated with ceftriaxone and metronidazole were compared to 233 patients treated with piperacillin/tazobactam.
Analysis of risk factors of infection in patients with inflammatory bowel disease.
Prz Gastroenterol
September 2024
Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.
Introduction: infection (CDI) is one of the most important challenges in contemporary gastroenterology. However, data from CDI studies are sometimes contradictory.
Aim: To analyse the risk factors for CDI in patients with inflammatory bowel disease (IBD).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!